Forbion's Dezima sold to Amgen
Dezima Pharma, a Dutch dyslipidemia drug developer backed by minority shareholders Forbion Capital Partners, BioGeneration Ventures and New Science Ventures since 2012, has been sold to US biopharma Amgen for $1.55bn.
More on Benelux
Gimv acquires majority stake in Witec
Belgium-based Gimv set to support Netherlands-headquartered contract design manufacturer’s growth
Bencis raises EUR 123m continuation fund for group of Fund IV assets
Secondary deal was led by Committed Advisors and will provide backing for future growth of four portfolio companies
Holland exits Mauritskliniek in sale to PE-backed Corius
Sale of Dutch dermatology group comes nine months after regulator blocked sale to Triton's Bergman
Unquote Private Equity Podcast: Growth equity's mounting momentum
Bregal Milestoneтs Cyrus Shey and HPE Growthтs Manfred Krikke discuss investing, operational support and what's next for the industry
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds